GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sigma Healthcare Ltd (OTCPK:SIGGF) » Definitions » Valuation Rank

SIGGF (Sigma Healthcare) Valuation Rank


View and export this data going back to 2009. Start your Free Trial

What is Sigma Healthcare Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sigma Healthcare Valuation Rank Related Terms

Thank you for viewing the detailed overview of Sigma Healthcare's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sigma Healthcare Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sigma Healthcare Ltd (OTCPK:SIGGF) » Definitions » Valuation Rank
Comparable Companies
ASX:PGC ASX:CYC MCK COR CAH SHSE:601607 HSIC HKSE:01099 SHSE:600332 MIL:AMP XSWX:GALE NZSE:EBO SHSE:600998 TSE:7459 SHSE:600511 PDCO TSE:2784 TSE:9987 SHSE:600739 SHSE:600056
Traded in Other Exchanges
S5YA:Germany SIG:Australia
Address
2125 Dandenong Road, Level 6, Clayton, Melbourne, VIC, AUS, 3168
Website
https://www.sigmahealthcare.com.au
Sigma Healthcare is an Australian pharmaceutical distributor, wholesaler and pharmacy franchisor. The revenue growth prospects and returns of pharmaceutical distribution are subdued due to ongoing Pharmaceutical Benefits Scheme, or PBS, price reform, and regulated wholesale gross margins being capped at 7% for community pharmacy. As a result, Sigma and its competitors are seeking to expand into unregulated revenue streams. In addition, pharmacy ownership is restricted to pharmacists, thereby excluding direct corporate ownership and requiring exposure via a franchise business model.